New York, NYCIK 18229474 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
13 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Abivax SA | 70.0K | $9.44M | 15.0% | +70.0K | New |
| 2 | Soleno Therapeutics Inc | 168.0K | $7.78M | 12.3% | −134.5K | Reduced |
| 3 | Atai Life Sciences NV | 1.71M | $7.01M | 11.1% | −573.9K | Reduced |
| 4 | Inventiva SA |
| 1.50M |
| $6.97M |
| 11.1% |
| +1.50M |
| New |
| 5 | Minerva Neurosciences Inc | 1.66M | $6.66M | 10.6% | +1.66M | New |
| 6 | Praxis Precision Medicines I | 19.9K | $5.86M | 9.3% | +19.9K | New |
| 7 | Edgewise Therapeutics Inc | 195.0K | $4.84M | 7.7% | +195.0K | New |
| 8 | Eupraxia Pharmaceuticals Inc | 397.9K | $3.00M | 4.8% | −517.1K | Reduced |
| 9 | Ovid Therapeutics Inc | 1.78M | $2.91M | 4.6% | +1.78M | New |
| 10 | Taysha Gene Therapies Inc | 457.1K | $2.51M | 4.0% | −1.44M | Reduced |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio